Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 408-414

  Scagliotti, G V ^a   Gridelli, C ^b   de Marinis, F ^c   Thomas, M ^d   Dediu, M ^e   Pujol, J L ^f   Manegold, C ^g   San Antonio, B ^h   Peterson, P M ⁱ   John, W ⁱ   Chouaki, N ⁱ   Visseren Grul, C ⁱ   Paz Ares, L G ^j  

^a UNIVERSITY OF TURIN   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h ELI LILLY AND COMPANY   (Spain)

ⁱ ELI LILLY AND COMPANY   (United States)

^j HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

more..

Author keywords

Carcinoma; Cisplatin; Induction chemotherapy; Maintenance chemotherapy; Non small cell lung; Nonsquamous; Pemetrexed; Phase III clinical trial

Indexed keywords

CISPLATIN; PEMETREXED; PLACEBO; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOPENIA; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; VOMITING; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; TREATMENT OUTCOME;

EID: 84926421370     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.07.005     Document Type: Article

References (23)

1. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small-cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-small Cell Lung Cancer. Version 3.2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
3. Peters S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E., et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(7 Suppl.):vii56-vii64.
4. Azzoli C.G., Temin S., Aliff T., Baker S., Brahmer J., Johnson D.H., et al. American Society of Clinical Oncology. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29:3825-3831. [Erratum in J Clin Oncol 2011;29:4725].
5. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
6. Scagliotti G., Brodowicz T., Shepherd F.A., Zielinski C., Vansteenkiste J., Manegold C., et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011, 6:64-70.
7. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
8. Paz-Ares L., de Marinis F., Dediu M., Thomas M., Pujol J.L., Bidoli P., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012, 13:247-255.
9. Paz-Ares L., de Marinis F., Dediu M., Thomas M., Pujol J.L., Bidoli P., et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013, 31:2895-2902.
10. Ou S.-H.I., Ziogas A., Zell J.A. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009, 4:1083-1093.
11. Belani C.P., Wu Y.L., Chen Y.M., Kim J.H., Yang S.H., Zhang L., et al. Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 2012, 7:567-573.
12. Reck M., von Pawel J., Zatloukal T., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234. [Erratum in J Clin Oncol 2009;27:2415].
13. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
14. Barlesi F., Scherpereel A., Rittmeyer A., Pazzola A., Ferrer Tur N., Kim J.H., et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013, 31:3004-3011.
15. Lustberg M.B., Edelman M.J. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol 2007, 8:38-46.
16. Socinski M.A., Stinchcombe T.E. Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol 2007, 25:5155-5157.
17. Soon Y.Y., Stockler M.R., Askie L.M., Boyer M. An updated systemic review and meta-analysis of randomized controlled trials on duration of chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2014, 32(Suppl.). [abstr 8104].
18. Gridelli C. Does palliative chemotherapy beyond three courses benefit patients with non-small cell lung cancer?. Nat Clin Pract 2007, 4:274-275.
19. Zinner R.G., Ross H.J., Weaver R., Govindan R., Holden V.R., Chowhan N.M., et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2013, 31(Suppl.). [abstr LBA8003].
20. Patel J.D., Socinski M.A., Garon E.B., Reynolds C.H., Spigel D.R., Olsen M.R., et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013, 31:4349-4357.
21. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14:253-263.
22. Sun J.-M., Park J.O., Won Y.-W., Kim J.H., Yun J., Lee J., et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small-cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol 2010, 5:540-545.
23. Gerber D.E., Schiller J.H. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 2013, 31:1009-1020.